Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 8, 2015British Journal of HaematologyOpen Access

Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory Primitive or Secondary Autoimmune Cytopenias: a single centre experience

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMaurizio MianoIstituto Giannina GasliniMSMaria ScalzoneBambino Gesù Children's HospitalKPKatia PerriIstituto Giannina Gaslini

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Miano et al. (2015) studied this question.

synapsesocial.com/papers/6a835f3b9ef178b4bb8cf423https://doi.org/10.1111/bjh.13533
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mycophenolate mofetil for the treatment of refractory auto‐immune haemolytic anaemia and auto‐immune thrombocytopenia purpura2002 · 153 citations
  2. 2Induced Regulatory T Cells Promote Tolerance When Stabilized by Rapamycin and IL-2 In Vivo2013 · 120 citations
  3. 3Rituximab for the treatment of refractory autoimmune hemolytic anemia in children2003 · 294 citations
  4. 4Empiric switch from calcineurin inhibitor to sirolimus‐based immunosuppression in pediatric heart transplantation recipients2013 · 22 citations
  5. 5Mycophenolate mofetil (MMF) for the treatment of steroid‐resistant idiopathic thrombocytopenic purpura2003 · 137 citations